Diabetic Eye Disease

The 3-year, $4.8 million award comes from the NIH Venture Program Oculomics Initiatives.

After reviewing information collected on a patient database, the team suggested telephone prompts for patients with mental health concerns, text message reminders, and online educational tools to improve uptake to increase eye screening attendance.

Brolucizumab significantly improves anatomic parameters of patients with diabetic macular edema.

Researchers set out to determine the most important systemic risk factors associated with cataract development in patients with DM.

Studies point to an inverse association between diabetes and keratoconus risk.

A recent paper sparks concerns over inadequate screening and management, especially among Black and Hispanic youths, according to its authors.

A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence LumineticsCore and testing for diabetic eye disease.

Understanding the latest innovative technologies.

A research team for the $3.3 million study will assess the front and the back of the eye and different types of glucose dysfunction.

It’s time to act with a few rational and relatively modest proposals.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, respectively.

The high-level analysis found in treatment follow-up that 82% of patients administered with TEPEZZA did not report needing any additional thyroid eye disease treatment for nearly 2 years.

Real-world insights can clear the path to trends and strategies to meet patients’ needs.

Amid conflicting findings, factors such as dosage, patient characteristics may affect outcomes.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

Older age and longer duration of type 1 diabetes also play a role in the development of diabetic retinopathy, according to a chart review.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

Community-based eye care is one of Orbis’s top priorities in the country.

Is telemedicine through retinal images a solution to earlier intervention and increased access to care? Fortunately—and unfortunately—yes.

Counsel your at-risk patients on strategies to minimize severe hypoglycemia.

T1D is one of the most common chronic diseases affecting pediatric populations.

A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.

As part of the American Diabetes Association's Health Equity Now program, the organization has partnered with Genentech, piloting a partnership within Alabama to specifically focusing on tackling barriers related to diabetic eye disease.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

The DR:EAM study in investigating novel eye drop OTT-166 for the treatment of diabetic retinopathy in hopes of reducing treatment burden for patients.

A look back on what happened in optometry during the week of March 20-March 24.

These disorders account for most of the vision loss in working-age and elderly Americans.